BRCA2 and breast cancer: The HISPANEL, including close to 100 recurrent mutations, has been applied in breast cancer patients from Mexico, Colombia, Peru and Brazil, with diverse results [29–32], due to the diversity of BRCA1 and BRCA2 mutations among different Latin American populations, and the variable criteria to select the patients to be analyzed.